mardi 24 avril 2018

Onco Actu du 24 avril 2018

1. Biologie

Researchers find five sub-types of the brain cancer glioma [Institute of Cancer Research]

3.4 Chimioprévention

Six in seven women at high risk of breast cancer shun tamoxifen as a preventative measure [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

In the Era of Precision Medicine and Big Data, Who Is Normal? [JAMA]

4.7 Dép., diag. & prono. - Col de l'utérus

How to redesign the vaginal speculum [The Guardian]

5. Traitements

A Drug To Treat Cancer And Heart Disease (Miracle Cure Or Media Hype?) [Forbes]

5.10 Traitements - Essais

Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug [NCI]

5.12 Immunothérapies

Remote-Control Shoots Laser at Nano-Gold to Turn on Cancer-Killing Immune Cells [Georgia Tech]

5.12.3 Immunothérapies-combinaisons

AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer [AstraZeneca]

AstraZeneca third-line lung cancer combination study fails [Reuters]

Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay [STAT]

5.15 ESTRO

Targeted radiotherapy for breast cancer offers good quality of life and fewer side effects [ESTRO]

Shorter courses of prostate cancer radiotherapy are safe and effective, and they could save patients’ time and reduce hospital waiting lists [ESTRO]

Correcting tiny differences in patient’s position for radiotherapy treatments could increase their survival chances [ESTRO]

Brachytherapy for cervical cancer patients does not increase the risk of ureteral stricture [ESTRO]

Handgrip strength test is a good indicator of survival in non-small cell lung cancer patients [ESTRO]

Elderly non-small cell lung cancer patients are less likely to benefit from treatment with simultaneous radio- and chemotherapy [ESTRO]

5.2 Pharma

Ex-Roche scientist Reed to head Sanofi R&D as Zerhouni retires [Reuters]

Epizyme Provides Update Regarding Tazemetostat Clinical Program [Epizyme]

FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case [EndPoints]

European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial [Merck]

5.2.2 Pharma - Fusions & Acquisitions

Takeda Can't Kick Its Shire Habit [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info [FiercePharma]

Conflict of Interest Among Public Speakers at FDA Advisory Committees [Penn LDI]

Pfizer Provides Update on Proposed Trastuzumab Biosimilar [Pfizer]

FDA declines to approve Pfizer's biosimilar to Roche's cancer drug [Reuters]

5.3.4 Traitements - AMM (FDA, EMA,...)

MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy [Pfizer]

5.9.4 AACR - poumon

Researchers Report Advances in Lung Cancer Immunotherapy [ACS]

5.9.5 AACR - CAR-T

AACR Annual Meeting 2018: Off-the-shelf CAR T-cell Immunotherapy – Are we There Yet? [Cancer Research Catalyst]

6. Lutte contre les cancers

Study: Winning an Early-Career Research Grant Begets More Funding [The Scientist]

Biden shakes Salk with powerful plea for more cancer cooperation [La Jolla Light]

Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing [Cell]

6.1 Observation

No increased risk of recurrence in breast cancer after reconstruction with abdominal tissue [Karolinsk Institutet]